Page last updated: 2024-08-24

triazoles and AMG-208

triazoles has been researched along with AMG-208 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amore, B; Beaupre, DM; Caudillo, I; Deng, H; Fu, S; Hong, DS; Hwang, YC; Janku, F; Khan, R; Kurzrock, R; Lee, P; Loberg, R; Lockhart, AC; Ngarmchamnanrith, G; Rosen, P	1

Trials

1 trial(s) available for triazoles and AMG-208

Article	Year
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget, 2015, Jul-30, Volume: 6, Issue:21 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Hypertension; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Remission Induction; Treatment Outcome; Triazoles	2015

Article

Year

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.

Oncotarget, 2015, Jul-30, Volume: 6, Issue:21

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Hypertension; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Remission Induction; Treatment Outcome; Triazoles

2015